TSXV:VER.H - Post by User
Comment by
andyranon Jul 10, 2012 8:39pm
165 Views
Post# 20100155
RE: RE: RE: RE: Sales estimates
RE: RE: RE: RE: Sales estimates Type when I said 500 units over 3 yeras. These numbers were 250, 350, 500 in year 1, 2, and 3. As stated, Zack's uses a potential of 900 devices sold in 2014 based on FDA approval in the US but I prefer not to assume that at all.
It seems more reasonable to me to assume that out of a starting market of 22,000 dermatologists, the company could reasonably capture 1,100 of those derms, or 5% - US approval would be icing on the cake but using even a 30% margin on my numbers would equate to $7.4M in year 3 and more as the 500 units from year 3 saw additional revenue from service contracts the following year. This is recurring revenue for a few years. That's $.13/share on the recurring revenue assuming 30% margins and 5% of market capture which could see the stock well north of $2 if it commands a large P/E which I think would be fully deserved.
The stock seems stupidly undervalued for the potential in my book. I added a few thousand more today and will keep adding as we near production.